Description

Glepaglutide (ZP1848) acetate, a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide acetate reduces faecal output and increases intestinal absorption. Glepaglutide acetate alleviates small intestinal inflammation. Glepaglutide acetate can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease[1][2][3].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)–COVID-19-immunoregulation–C199H329N53O57—-[1]Naimi RM, et al. a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial. Lancet Gastroenterol Hepatol. 2019 May;4(5):354-363. |[2]Janssen P, et al. Review article: a comparison of glucagon-like peptides 1 and 2. Aliment Pharmacol Ther. 2013 Jan;37(1):18-36. |[3]Jolanta Skarbaliene, et al. ZP1848, a Novel GLP-2 Agonist, Provides a Wide Window of Therapeutic Efficacy in the Experimental Crohn’s Disease Model. Gastroenterology, 2011, 140(5): S519. —-4376.06–98.47–[HGEGTFSSELATILDALAARDFIAWLIATKITDKKKKKK-NH2]–Inflammation/Immunology–H2O : ≥ 50 mg/mL–GCGR—-GPCR/G Protein–Peptides